Cellulitis : Clinical manifestations and management;Erysipèle : Manifestations cliniques et prise en charge

Revue Medicale Suisse

Volumn 9, Issue 401, 2013, Pages 1812-1815

  Blum, C L ^a   Menzinger, S ^a   Genne D ^a  

^a Hopital de la Chaux de Fonds   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ABSCESS; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CELLULITIS; DIABETES MELLITUS; DISEASE PREDISPOSITION; EDEMA; FASCIITIS; HUMAN; IMMUNE DEFICIENCY; SKIN INJURY; STREPTOCOCCUS GROUP A;

ANTI-BACTERIAL AGENTS; CELLULITIS; ERYSIPELAS; HUMANS; RECURRENCE; SECONDARY PREVENTION;

EID: 84887036559     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lipsky BA, Moran GJ, Napolitano LM, et al. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients : Clinical characteristics, medical treatment, and outcomes. BMC Infect Dis 2012;12:227.
2. Ellis Simonsen SM, van Orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect 2006;134:293-9. (Pubitemid 43280237)
3. Bonnetblanc JM, Doutre MS, Dreno B. (In Process Citation). Ann Dermatol Venereol 2012;139:A1-A2.
4. Leclerc S, Teixeira A, Mahe E, et al. Recurrent erysipelas : 47 cases. Dermatology 2007;214:52-7.
5. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406. (Pubitemid 41581713)
6. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin- resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355: 666-74.
7. Données de résistance, médecine humaine. www.anresis.ch.
8. Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004;350:904-12.
9. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children : Executive summary. Clin Infect Dis 2011;52:285-92.
10. Volluz SD, Abbet P, Troillet N. Quelle est la durée optimale de l'antibiothérapie pour les infections fréquentes ? Rev Med Suisse 2010;6:1901-5.
11. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas : A randomized, double blind, placebo-controlled study. Scand J Infect Dis 1997;29: 377-82.
12. Morpeth SC, Chambers ST, Gallagher K, et al. Lower limb cellulitis : Features associated with length of hospital stay. J Infect 2006;52:23-9. (Pubitemid 43115504)
13. Kremer M, Zuckerman R, Avraham Z, et al. Longterm antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect 1991;22:37-40.
14. Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 1997; 25:685-9.
15. Karppelin M, Siljander T, Huhtala H, et al. Recurrent cellulitis with benzathine penicillin prophylaxis is associated with diabetes and psoriasis. Eur J Clin Microbiol Infect Dis 2013;32:369-72.
16. Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections : The ESTABLISH-1 randomized trial. JAMA 2013;309:559-69.
17. Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164:1669-74. (Pubitemid 39037946)
18. Thomas K, Crook A, Foster K, et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg : Results of the UK Dermatology Clinical Trials Network's PATCH II trial. Br J Dermatol 2012;166:169- 78.